2024 Global Hemostasis Analyzers and Reagents: US, Europe, Japan--Supplier Shares and Strategies, Technology and Instrumentation Review, Emerging Opportunities

August 2024 | - | ID: 20DFED1168C6EN
Venture Planning Group

Abstracts

SummaryThis comprehensive seven-country report contains 650 pages, 150 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.The report explores business and technological trends in the US, Europe (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.RationaleThe growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromagenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.Coagulation TestsActivated Clotting Time (ACT) (1), Activated Protein C Resistance,Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, ; Factor IX,Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA
Sales and Market Share Analysis%li%Sales and market shares of major instrument and reagent suppliers.Competitive Assessments%li%Extensive strategic profiles ofmajor suppliers and emerging market entrants.Market Segmentation Analysis%li%Comprehensive marketsegmentation analysis, including: %li%Hospitals %li%Commercial/Private Laboratories %li%Physician Offices %li%Ambulatory Care Centers%li%Test volume forecasts & for over 40 major procedures,by country and market segment.Current and Emerging Products%li%Review of established and emerging procedures.%li%Comparison of automated and semi-automatedanalyzers from Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.Technology Review%li%Analysis of current and emerging technologies and their potential market applications.%li%Comprehensive lists of companies developingor marketing new technologies and products by test.Worldwide Market Overview%li%Estimates of facilities performing coagulation testsby country.%li%Test volume and sales projections by country.Strategic Recommendations%li%Product development and business expansion opportunities with significant market appeal.%li%“Ideal” product models with tentativeprices and operating characteristics.%li%Alternative market penetrationstrategies for instrument and reagent suppliers.%li%Potential market entry barriers and risks.Contains 650 pages and 150 tables

Contents

I. Introduction
II. Major Product Development Opportunities
III. Design Criteria For Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Overview
A. Major Routine and Special Coagulation Tests

1. INTRODUCTION

2. ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

3. ALPHA-2 ANTIPLASMIN

4. ANTITHROMBIN III

5. BLEEDING TIME

6. D-DIMER

7. ETHANOL FLOCCULATION TEST

8. EUGLOBULIN LYSIS

9. FACTOR ASSAYS

a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII
Table of Contents (continued)

10. FIBRIN DEGRADATION PRODUCTS

11. FIBRINOGEN

12. HEPARIN

13. HIRUDIN

14. HYPERCOAGULABILITY AND THROMBOSIS

15. LIPOPROTEIN A

16. PLASMIN

17. PLASMINOGEN

18. PLASMINOGEN ACTIVATOR INHIBITOR (PAI)

19. PLATELET FUNCTION TESTS

20. PLATELET AGGREGATION

21. PROTEINS C AND S

22. PROTHROMBIN FRAGMENT 1.2

23. PROTHROMBIN TIME (PT)

24. REPTILASE TIME

25. THROMBIN TIME

26. TISSUE-TYPE PLASMINOGEN ACTIVATOR (T-PA)

27. VON WILLEBRAND'S FACTOR

B. Coagulation Instrumentation Review: Centralized
and POC Testing Analyzers
C. Major Coagulation Testing Technologies
and Their Potential Applications

1. CHROMOGENIC SUBSTRATES

2. MONOCLONAL AND POLYCLONAL ANTIBODIES

3. IMMUNOASSAYS

4. MOLECULAR DIAGNOSTICS

5. MICROCOMPUTERS

6. AUTOMATION

7. ROBOTICS

8. ARTIFICIAL INTELLIGENCE

9. DRY CHEMISTRY

10. BISENSORS

VII. Country Market Size, Test Volume
and Sales Forecasts by Segment, Major
Instrument and Reagent Suppliers Market
Shares